Literature DB >> 24108778

Evaluation of a prototype flow cytometry test for serodiagnosis of canine visceral leishmaniasis.

Henrique Gama Ker1, Wendel Coura-Vital, Rodrigo Dian de Oliveira Aguiar-Soares, Bruno Mendes Roatt, Nádia das Dores Moreira, Cláudia Martins Carneiro, Evandro Marques de Menezes Machado, Andréa Teixeira-Carvalho, Olindo Assis Martins-Filho, Rodolfo Cordeiro Giunchetti, Márcio Sobreira Silva Araújo, Eduardo Antonio Ferraz Coelho, Denise da Silveira-Lemos, Alexandre Barbosa Reis.   

Abstract

Diagnosing canine visceral leishmaniasis (CVL) is a critical challenge since conventional immunoserological tests still present some deficiencies. The current study evaluated a prototype flow cytometry serology test, using antigens and fluorescent antibodies that had been stored for 1 year at 4°C, on a broad range of serum samples. Noninfected control dogs and Leishmania infantum-infected dogs were tested, and the prototype test showed excellent performance in differentiating these groups with high sensitivity, specificity, positive and negative predictive values, and accuracy (100% in all analyses). When the CVL group was evaluated according to the dogs' clinical status, the prototype test showed outstanding accuracy in all groups with positive serology (asymptomatic II, oligosymptomatic, and symptomatic). However, in dogs which had positive results by PCR-restriction fragment length polymorphism (RFLP) but negative results by conventional serology (asymptomatic I), serological reactivity was not observed. Additionally, sera from 40 dogs immunized with different vaccines (Leishmune, Leish-Tec, or LBSap) did not present serological reactivity in the prototype test. Eighty-eight dogs infected with other pathogens (Trypanosoma cruzi, Leishmania braziliensis, Ehrlichia canis, and Babesia canis) were used to determine cross-reactivity and specificity, and the prototype test performed well, particularly in dogs infected with B. canis and E. canis (100% and 93.3% specificities, respectively). In conclusion, our data reinforce the potential of the prototype test for use as a commercial kit and highlight its outstanding performance even after storage for 1 year at 4°C. Moreover, the prototype test efficiently provided accurate CVL serodiagnosis with an absence of false-positive results in vaccinated dogs and minor cross-reactivity against other canine pathogens.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24108778      PMCID: PMC3889512          DOI: 10.1128/CVI.00575-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  32 in total

Review 1.  The biology and control of phlebotomine sand flies.

Authors:  R Killick-Kendrick
Journal:  Clin Dermatol       Date:  1999 May-Jun       Impact factor: 3.541

2.  GROWTH AND DIFFERENTIATION IN TRYPANOSOMA CRUZI. I. ORIGIN OF METACYCLIC TRYPANOSOMES IN LIQUID MEDIA.

Authors:  E P CAMARGO
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1964 May-Jun       Impact factor: 1.846

3.  Shared resource laboratories: impact of new design criteria to consolidate flow cytometry diagnostic service.

Authors:  F Monti; M Rosetti; P Masperi; N Tommasini; R M Dorizzi
Journal:  Int J Lab Hematol       Date:  2012-05-21       Impact factor: 2.877

4.  Domestic dog ownership in Iran is a risk factor for human infection with Leishmania infantum.

Authors:  A Samad Mazloumi Gavgani; Hassan Mohite; Gholan H Edrissian; Mehdi Mohebali; Clive R Davies
Journal:  Am J Trop Med Hyg       Date:  2002-11       Impact factor: 2.345

5.  Evaluation of a novel chromatographic immunoassay based on Dual-Path Platform technology (DPP® CVL rapid test) for the serodiagnosis of canine visceral leishmaniasis.

Authors:  Gabriel Grimaldi; Antonio Teva; Adelson L Ferreira; Claudiney B dos Santos; Israel de-Souza Pinto; Carolina T de-Azevedo; Aloísio Falqueto
Journal:  Trans R Soc Trop Med Hyg       Date:  2012-01       Impact factor: 2.184

6.  Canine visceral leishmaniosis: a comparative analysis of the EIE-leishmaniose-visceral-canina-Bio-Manguinhos and the IFI-leishmaniose-visceral-canina-Bio-Manguinhos kits.

Authors:  R A Lira; M Paiva Cavalcanti; M Nakazawa; A G P Ferreira; E D Silva; F G C Abath; L C Alves; W V Souza; Y M Gomes
Journal:  Vet Parasitol       Date:  2006-01-30       Impact factor: 2.738

7.  Anti-fixed Leishmania chagasi promastigotes IgG antibodies detected by flow cytometry (FC-AFPA-IgG) as a tool for serodiagnosis and for post-therapeutic cure assessment in American visceral leishmaniasis.

Authors:  Lúcia Maria Garcia; Jordana Grazziela Alves Coelho-Dos-Reis; Vanessa Peruhype-Magalhães; Andréa Teixeira-Carvalho; Roberta Dias Rodrigues Rocha; Márcio Sobreira Silva Araújo; Izabelle Teixeira Gomes; Sílvio Fernando Guimarães Carvalho; Reynaldo Dietze; Elenice Moreira Lemos; Mariléia Chaves Andrade; Olindo Assis Martins-Filho
Journal:  J Immunol Methods       Date:  2009-07-25       Impact factor: 2.303

Review 8.  Canine leishmaniosis - new concepts and insights on an expanding zoonosis: part one.

Authors:  Gad Baneth; Alexander F Koutinas; Laia Solano-Gallego; Patrick Bourdeau; Lluis Ferrer
Journal:  Trends Parasitol       Date:  2008-05-29

9.  Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation.

Authors:  Bruno Mendes Roatt; Rodrigo Dian de Oliveira Aguiar-Soares; Juliana Vitoriano-Souza; Wendel Coura-Vital; Samuel Leôncio Braga; Rodrigo Corrêa-Oliveira; Olindo Assis Martins-Filho; Andréa Teixeira-Carvalho; Marta de Lana; Nelder Figueiredo Gontijo; Marcos José Marques; Rodolfo Cordeiro Giunchetti; Alexandre Barbosa Reis
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

10.  Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs.

Authors:  Rodolfo Cordeiro Giunchetti; Rodrigo Corrêa-Oliveira; Olindo Assis Martins-Filho; Andréa Teixeira-Carvalho; Bruno Mendes Roatt; Rodrigo Dian de Oliveira Aguiar-Soares; Juliana Vitoriano de Souza; Nádia das Dores Moreira; Luiz Cosme Cotta Malaquias; Luciana Lisboa Mota e Castro; Marta de Lana; Alexandre Barbosa Reis
Journal:  Vaccine       Date:  2007-08-24       Impact factor: 3.641

View more
  4 in total

1.  Leishmaniases diagnosis: an update on the use of immunological and molecular tools.

Authors:  Milena de Paiva-Cavalcanti; Rayana Carla Silva de Morais; Rômulo Pessoa-E-Silva; Lays Adrianne Mendonça Trajano-Silva; Suênia da Cunha Gonçalves-de-Albuquerque; Diego de Hollanda Cavalcanti Tavares; Maria Carolina Accioly Brelaz-de-Castro; Rafael de Freitas E Silva; Valéria Rêgo Alves Pereira
Journal:  Cell Biosci       Date:  2015-06-17       Impact factor: 7.133

2.  Comparison of a qualitative immunochromatographic test with two quantitative serological assays for the detection of antibodies to Leishmania infantum in dogs.

Authors:  Sergio Villanueva-Saz; Asier Basurco; Víctor Martín; Antonio Fernández; Araceli Loste; María Teresa Verde
Journal:  Acta Vet Scand       Date:  2019-08-07       Impact factor: 1.695

3.  Improving the serodiagnosis of canine Leishmania infantum infection in geographical areas of Brazil with different disease prevalence.

Authors:  Laura Ramírez; Luana Dias de Moura; Natalia Lopes Fontoura Mateus; Milene Hoehr de Moraes; Leopoldo Fabrício Marçal do Nascimento; Nailson de Jesus Melo; Lucas Bezerra Taketa; Tatiana Catecati; Samuel G Huete; Karla Penichet; Eliane Mattos Piranda; Alessandra Gutierrez de Oliveira; Mario Steindel; Manoel Barral-Netto; Maria do Socorro Pires E Cruz; Aldina Barral; Manuel Soto
Journal:  Parasite Epidemiol Control       Date:  2019-11-21

4.  Phase I and II Clinical Trial Comparing the LBSap, Leishmune®, and Leish-Tec® Vaccines against Canine Visceral Leishmaniasis.

Authors:  Rodrigo Dian de Oliveira Aguiar-Soares; Bruno Mendes Roatt; Fernando Augusto Siqueira Mathias; Levi Eduardo Soares Reis; Jamille Mirelle de Oliveira Cardoso; Rory Cristiane Fortes de Brito; Henrique Gama Ker; Rodrigo Corrêa-Oliveira; Rodolfo Cordeiro Giunchetti; Alexandre Barbosa Reis
Journal:  Vaccines (Basel)       Date:  2020-11-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.